Bone Biologics Corp
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| (a) | Exhibits required by Item 601 of Regulation S-K. |
| Incorporated by reference | |||||
|---|---|---|---|---|---|
| Exhibit · (unless otherwise indicated) | |||||
| Number | Exhibit Title | Form | File | Exhibit | Filing date |
| 4.1 | Form of Series F Warrant dated July 9, 2026 | 8-K | 001-40899 | 4.1 | July 9, 2026 |
| 4.2 | Form of Series G Warrant dated July 9, 2026 | 8-K | 001-40899 | 4.2 | July 9, 2026 |
| 4.3 | Form of Pre-Funded Warrant dated July 9, 2026 | 8-K | 001-40899 | 4.3 | July 9, 2026 |
| 4.4 | Form of Placement Agent Warrant dated July 9, 2026 | 8-K | 001-40899 | 4.4 | July 9, 2026 |
| 10.1 | Form of Securities Purchase Agreement dated July 7, 2026 | 8-K | 001-40899 | 10.1 | July 9, 2026 |
| 10.2 | Form of Registration Rights Agreement dated July 7, 2026 | 8-K | 001-40899 | 10.2 | July 9, 2026 |
| 31.1* | Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended June 30, 2026. | — | — | — | — |
| 31.2* | Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended June 30, 2026. | — | — | — | — |
| 32.1** | Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 32.2** | Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 101.INS* | Inline XBRL Instance Document | — | — | — | — |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | — | — | — | — |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | — | — | — | — |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | — | — | — | — |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | — | — | — | — |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | — | — | — | — |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed Herewith
** Furnished Herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.